DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Table 25–9
Vasopressin Receptor Antagonists (Continued)
C. V 2
-selective antagonists (cont.)
OPC-31260 (mozavaptan) c
H3C CH 3
N
OPC-41061 (tolvaptan) c
O
N
Cl
OH
O
NH
N
CO
NHCO
H 3C
D. V 1a
-/V 2
-selective antagonists
YM-471
YM 087 (conivaptan) c
CH 3 CH 3
CH 3
N
N
F
F
N
NH
O
O
HN
N
O
N
CH 3
O O
N
H
JTV-605
S
CL-385004
N
O
N
O
O(CH 2) 3C
N
N
CH 3
CH 3
O
N
N
O
NH
O
NH
CH 3
F
H 3C
a
Also blocks V 1a
receptor, b C
rather than H 2C
CH 2 CH 2
C
H 3C
CH 2 CH 2
V 2
antagonistic activity in rats; however, antagonistic activity may be less or nonexistent in other species. Also, with prolonged infusion may exhibit
significant agonist activity. c Available for clinical use.